MDCX
Medicus Pharma Ltd. Common Stock
NASDAQ · Healthcare · Biotechnology · CA
$0.17
+0.88%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
Market Cap
$10.87M
MomentumView details →
1D Return
+0.88%
YTD Return
−88.32%
RSI (14)
29.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
Market Cap
$10.87M
RSI (14)
29.6
MomentumView details →
1D Return
+0.88%
YTD Return
−88.32%
SummaryUpdated Jun 1, 2026
Medicus Pharma Ltd. (NASDAQ:MDCX) is a clinical-stage biotechnology company that went public in November 2024. Founded as a biotech venture focused on developing innovative cancer treatments, the company specializes in advancing non-invasive therapeutic solutions for skin cancer. As a recently public entity, Medicus represents an early-stage biotech firm transitioning from private development to public markets while pursuing clinical trials for its novel therapeutic candidates.
Similar companies
Latest newsMore news →
Medicus Pharma Ltd. signed a Co-Development and License Agreement with Pfizer Inc., under which Pfizer granted Medicus an exclusive worldwide license to develop, manufacture and commercialize PF-08046031 (CD228V), with Medicus paying a $12.0 million upfront fee and Pfizer paying a $2.0 million development funding payment.1d agoMedicus Pharma raised about $40 million through equity and debt financing during the first half of 2026.22d agoMedicus Pharma Ltd. reported financial results for the three and six months ended June 30, 2026, and provided a corporate update on its development programs.23d ago